In collaboration with Merck Research Laboratories, we have demonstrated that conjugating Pfs25 with OMPC, the Outer Membrane Protein Complex of the Neisseria meningitides subgroup B, significantly increased immunogenicity and response longevity of Pfs25 in multiple animal models, including non human primates. The induced immune sera effectively blocked malaria transmission as evaluated in an ex-vivo membrane feeding assay. The collaborative efforts continues to evaluate conjugates using different carriers and adjuvants, in searching for a cost-effective process for vaccine product development. Studies to evaluate other transmission blocking vaccine candidates, Pfs230 and Pvs25, have also been initiated.
|MacDonald, Nicholas J; Nguyen, Vu; Shimp, Richard et al. (2016) Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230. J Biol Chem 291:19913-22|
|Jones, David S; Rowe, Christopher G; Chen, Beth et al. (2016) A Method for Producing Protein Nanoparticles with Applications in Vaccines. PLoS One 11:e0138761|
|Wu, Yimin; Sinden, Robert E; Churcher, Thomas S et al. (2015) Development of malaria transmission-blocking vaccines: from concept to product. Adv Parasitol 89:109-52|
|Cheru, Lediya; Wu, Yimin; Diouf, Ababacar et al. (2010) The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species. Vaccine 28:4423-9|
|Kubler-Kielb, Joanna; Majadly, Fathy; Biesova, Zuzana et al. (2010) A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates. Proc Natl Acad Sci U S A 107:1172-7|